316 related articles for article (PubMed ID: 11154141)
1. Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET).
Høibraaten E; Qvigstad E; Arnesen H; Larsen S; Wickstrøm E; Sandset PM
Thromb Haemost; 2000 Dec; 84(6):961-7. PubMed ID: 11154141
[TBL] [Abstract][Full Text] [Related]
2. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial.
Høibraaten E; Qvigstad E; Andersen TO; Mowinckel MC; Sandset PM
Thromb Haemost; 2001 May; 85(5):775-81. PubMed ID: 11372667
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy.
Lowe G; Woodward M; Vessey M; Rumley A; Gough P; Daly E
Thromb Haemost; 2000 Apr; 83(4):530-5. PubMed ID: 10780311
[TBL] [Abstract][Full Text] [Related]
4. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.
Straczek C; Oger E; Yon de Jonage-Canonico MB; Plu-Bureau G; Conard J; Meyer G; Alhenc-Gelas M; Lévesque H; Trillot N; Barrellier MT; Wahl D; Emmerich J; Scarabin PY;
Circulation; 2005 Nov; 112(22):3495-500. PubMed ID: 16301339
[TBL] [Abstract][Full Text] [Related]
5. Hormone replacement therapy with estradiol and risk of venous thromboembolism--a population-based case-control study.
Høibraaten E; Abdelnoor M; Sandset PM
Thromb Haemost; 1999 Oct; 82(4):1218-21. PubMed ID: 10544901
[TBL] [Abstract][Full Text] [Related]
6. Thromboembolism during hormone therapy in Japanese women.
Adachi T; Sakamoto S
Semin Thromb Hemost; 2005 Jun; 31(3):272-80. PubMed ID: 16052396
[TBL] [Abstract][Full Text] [Related]
7. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis.
Eilertsen AL; Høibraaten E; Os I; Andersen TO; Sandvik L; Sandset PM
Maturitas; 2005 Oct; 52(2):111-8. PubMed ID: 16186073
[TBL] [Abstract][Full Text] [Related]
8. Hormone replacement therapy does not affect the 24-hour heart rate variability in postmenopausal women: results of a randomized, placebo-controlled trial with two regimens.
Fernandes EO; Moraes RS; Ferlin EL; Wender MC; Ribeiro JP
Pacing Clin Electrophysiol; 2005 Jan; 28 Suppl 1():S172-7. PubMed ID: 15683490
[TBL] [Abstract][Full Text] [Related]
9. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review.
Gomes MP; Deitcher SR
Arch Intern Med; 2004 Oct; 164(18):1965-76. PubMed ID: 15477430
[TBL] [Abstract][Full Text] [Related]
10. Postmenopausal hormone therapy and the risk of venous thromboembolism.
Rachoń D; Teede H
Climacteric; 2008 Aug; 11(4):273-9. PubMed ID: 18645692
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
Eriksson H; Lundström T; Wåhlander K; Clason SB; Schulman S;
Thromb Haemost; 2005 Sep; 94(3):522-7. PubMed ID: 16268466
[TBL] [Abstract][Full Text] [Related]
12. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy.
Douketis JD; Ginsberg JS; Holbrook A; Crowther M; Duku EK; Burrows RF
Arch Intern Med; 1997 Jul; 157(14):1522-30. PubMed ID: 9236553
[TBL] [Abstract][Full Text] [Related]
13. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
[TBL] [Abstract][Full Text] [Related]
14. Sex and gender issues and venous thromboembolism.
Moores L; Bilello KL; Murin S
Clin Chest Med; 2004 Jun; 25(2):281-97. PubMed ID: 15099889
[TBL] [Abstract][Full Text] [Related]
15. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.
Canonico M; Oger E; Plu-Bureau G; Conard J; Meyer G; Lévesque H; Trillot N; Barrellier MT; Wahl D; Emmerich J; Scarabin PY;
Circulation; 2007 Feb; 115(7):840-5. PubMed ID: 17309934
[TBL] [Abstract][Full Text] [Related]
16. Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study.
Glynn RJ; Ridker PM; Goldhaber SZ; Zee RY; Buring JE
Circulation; 2007 Sep; 116(13):1497-503. PubMed ID: 17846285
[TBL] [Abstract][Full Text] [Related]
17. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.
Eriksson BI; Lassen MR;
Arch Intern Med; 2003 Jun; 163(11):1337-42. PubMed ID: 12796070
[TBL] [Abstract][Full Text] [Related]
18. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women.
Olié V; Plu-Bureau G; Conard J; Horellou MH; Canonico M; Scarabin PY
Menopause; 2011 May; 18(5):488-93. PubMed ID: 21178641
[TBL] [Abstract][Full Text] [Related]
19. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer.
Duggan C; Marriott K; Edwards R; Cuzick J
J Clin Oncol; 2003 Oct; 21(19):3588-93. PubMed ID: 14512389
[TBL] [Abstract][Full Text] [Related]
20. The prevalence of thrombophilia and venous thromboembolism in total knee arthroplasty.
Chotanaphuti T; Ongnamthip P; Silpipat S; Foojareonyos T; Roschan S; Reumthantong A
J Med Assoc Thai; 2007 Jul; 90(7):1342-7. PubMed ID: 17710975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
